Anti-α-synuclein immunotherapy reduces α-synuclein propagation in the axon and degeneration in a combined viral vector and transgenic model of synucleinopathy.
about
Pharmacological effects of protocatechuic acid and its therapeutic potential in neurodegenerative diseases: Review on the basis of in vitro and in vivo studies in rodents and humans.A novel panel of α-synuclein antibodies reveal distinctive staining profiles in synucleinopathies.In vivo models of alpha-synuclein transmission and propagation.The Evidence for the Spread and Seeding Capacities of the Mutant Huntingtin Protein in in Vitro Systems and Their Therapeutic Implications.Mini-review on initiatives to interfere with the propagation and clearance of alpha-synuclein in Parkinson's disease.Dementia with Lewy bodies and Parkinson's disease-dementia: current concepts and controversies.Are dementia with Lewy bodies and Parkinson's disease dementia the same disease?Region-Specific Effects of Immunotherapy With Antibodies Targeting α-synuclein in a Transgenic Model of Synucleinopathy.Progressive Decline in Gray and White Matter Integrity in Parkinson's Disease: An Analysis of Longitudinal Parkinson Progression Markers Initiative Diffusion Tensor Imaging DataLRRK2 kinase regulates α-synuclein propagation via RAB35 phosphorylationProteasome-targeted nanobodies alleviate pathology and functional decline in an α-synuclein-based Parkinson's disease modelImmunotherapy targeting toll-like receptor 2 alleviates neurodegeneration in models of synucleinopathy by modulating α-synuclein transmission and neuroinflammationMicroglia Response During Parkinson's Disease: Alpha-Synuclein Intervention
P2860
Q38651654-BA6BA7BF-8FF5-4B53-8527-D76C57A24852Q41069719-ED78DCEE-7AF7-49BC-A043-74A4CD8EDC7BQ46252300-617D89F3-82D0-490F-86D7-87BBFAF8E61CQ47102449-8013F59B-04DD-4C2B-AB54-5103AB039E08Q47123483-B3E581D6-F44A-415D-8D1D-BF68E8AB6D14Q49987358-C1990CA4-EC07-4186-8732-4CCA1AD2FE01Q54982491-DE1F2DEA-4D13-45B7-A83F-04AB365E2B3CQ55691017-5BF0EE6A-883F-43C4-B168-FE9E7A7930DEQ57817384-9A45022B-9EB9-4821-82C5-9C6D3E983137Q58701452-E32B3E8B-096B-4B37-8070-6A032A3D59A3Q58722552-AC1FEA29-C71D-4D97-8DEF-CB63DC4CBD30Q58793525-A9EF2775-203F-4597-ADD8-6DCA5996F784Q58799080-43FDA6E3-9965-4C56-B85C-C4E2BB798B70
P2860
Anti-α-synuclein immunotherapy reduces α-synuclein propagation in the axon and degeneration in a combined viral vector and transgenic model of synucleinopathy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 13 January 2017
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Anti-α-synuclein immunotherapy ...... enic model of synucleinopathy.
@en
Anti-α-synuclein immunotherapy ...... enic model of synucleinopathy.
@nl
type
label
Anti-α-synuclein immunotherapy ...... enic model of synucleinopathy.
@en
Anti-α-synuclein immunotherapy ...... enic model of synucleinopathy.
@nl
prefLabel
Anti-α-synuclein immunotherapy ...... enic model of synucleinopathy.
@en
Anti-α-synuclein immunotherapy ...... enic model of synucleinopathy.
@nl
P2093
P2860
P1476
Anti-α-synuclein immunotherapy ...... enic model of synucleinopathy.
@en
P2093
Anthony Adame
Brian Spencer
Cassia Overk
Dale Schenk
Dora Games
Elvira Valera
Michael Mante
Peter Seubert
Robert A Rissman
Robin Barbour
P2860
P2888
P356
10.1186/S40478-016-0410-8
P577
2017-01-13T00:00:00Z
P6179
1018539465